**利拉利汀**（**Linagliptin**），或称利格列汀，屬於新一代DPP-4抑制劑（dipeptidyl peptidase
(DPP)-4
inhibitors）的[糖尿病藥物](../Page/糖尿病.md "wikilink")，於2011年5月獲[美國食品及藥物管理局](https://zh.wikipedia.org/wiki/美國食品及藥物管理局 "wikilink")(FDA)核准，在配合飲食及運動下，用於治療成年人[二型糖尿病](https://zh.wikipedia.org/wiki/二型糖尿病 "wikilink")\[1\]。「利拉利汀」是目前唯一一種非主經腎臟排出體外的DPP-4抑制劑口服抗糖尿病藥。多項研究發現，只有5%
的「利拉利汀」藥物由腎臟排出\[2\]，其餘大部分未經代謝的藥物會由膽汁及腸道排泄出來，並不如其他同類口服糖尿病藥物(如﹕[Sitagliptin](https://zh.wikipedia.org/wiki/Sitagliptin "wikilink")「[西他列汀](https://zh.wikipedia.org/wiki/西他列汀 "wikilink")」、[Vildagliptin](https://zh.wikipedia.org/wiki/Vildagliptin "wikilink")「[維格列汀](https://zh.wikipedia.org/wiki/維格列汀 "wikilink")」及[Saxagliptin](https://zh.wikipedia.org/wiki/Saxagliptin "wikilink")「[沙格列汀](../Page/沙格列汀.md "wikilink")」)
有近7成至9成經腎臟排出 \[3\]\[4\]\[5\]\[6\] 。

「利拉利汀」由德國藥廠研發，與美國藥廠共同推廣，商品名為Trajenta，中文商品則名為 「糖漸平」(台灣)
、「糖安達」（香港）或「歐唐寧」（中國大陸）。

## 作用機制

[二肽基肽酶-4](../Page/二肽基肽酶-4.md "wikilink")（DPP-4）是人體酵素的一種，能迅速分解兩種腸促胰島素，包括胰升糖素樣肽（GLP-1）及腸抑胃肽（GIP）。GLP-1和GIP的功能，是刺激胰臟beta細胞製造及分泌胰島素，特別是在進食後血糖水平升高時。GLP-1還有另一項功能，就是抑制胰臟alpha細胞分泌胰升糖素，從而減少肝糖的製造。因此，作為DPP-4抑制劑，「利拉利汀」(linagliptin)
能夠在血糖濃度高時黏附於DPP-4上，阻止其分解腸促胰島素\[7\]，延長GLP-1和GIP的壽命，從而促進胰島素分泌，降低胰升糖素水平，改善血糖控制。

DPP-4抑制劑標誌着二型糖尿病治療的一個創新方向，作用機制獨特，與其他類型的二型糖尿病藥物有別。

## 臨床研究

[缩略图](https://zh.wikipedia.org/wiki/File:Linagliptin_Synthesis.svg "fig:缩略图")
「利拉利汀」(linagliptin)已完成第三期臨床試驗計劃，以証實單獨治療及合併其他常用抗糖尿病藥（例如[甲福明](https://zh.wikipedia.org/wiki/甲福明 "wikilink")、[磺胺脲類或](https://zh.wikipedia.org/wiki/磺胺脲類 "wikilink")[格列酮類](https://zh.wikipedia.org/wiki/格列酮類 "wikilink")）的療效、安全性與耐受性。整個計劃的試驗中心分佈全球約40個國家，共納入超過5,000名二型糖尿病病人，當中有過千名病人患有不同程度的腎功能受損，因此臨床試驗計劃中亦包括兩項獨立的長期研究，集中評估「利拉利汀」對治療輕度、中度及重度腎功能受損的二型糖尿病病人的安全性及療效\[8\]
\[9\]\[10\]\[11\]\[12\] \[13\]\[14\]\[15\]\[16\]。

## 療效

整體研究結果顯示\[17\] \[18\]\[19\]\[20\]\[21\]
\[22\]\[23\]\[24\]，無論單獨治療或合併其他抗糖尿病藥物如甲福明、磺胺脲類或格列酮類，「利拉利汀」(linagliptin)的控糖療效均十分顯著、持久而且具臨床意義。八項隨機對照研究共納入5,239名二型糖尿病病人，評估「利拉利汀」的療效和安全性。共有3,319名二型糖尿病病人接受「利拉利汀」治療，當中929名年齡65歲或以上；1,238名患有輕度腎功能受損；143名患有中度腎功能受損。結果證實，每天一次「利拉利汀」能顯著改善血糖控制，對病人體重並沒有造成具臨床意義的影響。所有子群組（性別、年齡、腎功能受損程度、體重指數）的糖化血紅素下降幅度相若。

部分研究更發現 ，「利拉利汀」能大幅改善beta細胞的功能（beta細胞負責製造及分泌胰島素）\[25\]\[26\]\[27\]
\[28\]\[29\]。

另外一項為期逾兩年的長期研究\[30\]，比較「利拉利汀」或格列美脲加入甲福明治療後的效果12。結果顯示，「利拉利汀」能有效降糖，療效不但與格列美脲相若，而且不會引致體重上升，出現血糖過低的風險較格列美脲低，發生心血
管事件的情況也較少。目前的臨床研究証實「利拉利汀」有以下的特點：

  - 持久穩定血糖至理想目標，具有臨床意義
  - 安全性及耐受性良好，血糖過低的風險相當低
  - 不會引致體重上升
  - 無須調節藥物劑量。即使服用者同時患有其他疾病或服用其他藥物，甚至有腎功能受損，也無須調校「利拉利汀」的用藥劑量（「利拉利汀」並非主要依靠腎臟排出體外）。

## 安全性與耐受性

「利拉利汀」的整體副作用發生率與安慰劑相若，耐受性佳\[31\]\[32\]\[33\]
\[34\]\[35\]。即使單獨用藥或合併其他抗糖尿病藥物如甲福明、磺胺脲類或格列酮類，病人出現血糖過低的風險並無顯著增加。當與其他常用的抗糖尿病藥物合併治療，「利拉利汀」亦無產生明顯的藥物相互作用，意味着不論病人是否患有其他疾病或同時服用其他常見的藥物，都適合接受「利拉利汀」治療\[36\]\[37\]。與磺胺脲類、
格列酮類或胰島素治療不同，「利拉利汀」並不會引致體重上升，亦不會產生傳統抗糖尿病藥常見的副作用\[38\]。與許多傳統二型糖尿病治療相反，開始「利拉利汀」治療時，病人無需經歷一段劑量調校期（即逐步增加劑量）以找出適當的治療劑量。

## 劑量

「利拉利汀」的一般劑量是5毫克藥片。

## 不宜服用的人士

  - 對「利拉利汀」有效成分過敏
  - 患有一型糖尿病
  - 有糖尿病酮症酸中毒症
  - 懷孕、正在授乳或準備授乳

## 副作用

研究証實少數服用者會出現血糖過低的情況，而極少數服用者會出現過敏的情況。

## 参考文献

[Category:炔烃](https://zh.wikipedia.org/wiki/Category:炔烃 "wikilink")
[Category:哌啶](https://zh.wikipedia.org/wiki/Category:哌啶 "wikilink")
[Category:喹唑啉](https://zh.wikipedia.org/wiki/Category:喹唑啉 "wikilink")
[Category:黄嘌呤类](https://zh.wikipedia.org/wiki/Category:黄嘌呤类 "wikilink")

1.  FDA approves new treatment for Type 2 diabetes. 3 May 2011.
    Available at:
    <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm>.
    Accessed 25 February 2012.
2.  Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K.
    The metabolism and disposition of the oral dipeptidyl peptidase-4
    inhibitor, linagliptin, in humans. Drug Metab Dispos 2010
    Apr;38(4):667-678.
3.  Carolyn F Deacon, Jens J Holst. Dipeptidyl peptidase-4 inhibitors
    for the treatment of type 2 diabetes: comparison, efficacy and
    safety. Informa Healthcare Expert Opinion Reviews. October 2013,
    Vol. 14, No. 15 , Pages 2047-2058.
4.  Sitagliptin summary of product characteristics. Available at
    www.medicines.org.uk/emc/medicine/19609.
5.  Vildaliptin summary of product characteristics. Available at
    www.medicines.org.uk/emc/medicine/20734.
6.  Saxagliptin summary of product characteristics. Available at
    www.medicines.org.uk/EMC/medicine/22315.
7.  Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl
    peptidase-4 inhibitor BI 135
    \[(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazol
    in-2-ylmethyl)-3,7-dihydro-purine-2,6-dione\] increases basal
    glucagon-like peptide-1 and improves glycemic control in diabetic
    rodent models. J Pharmacol Exp Ther 2009;328(2):556-563.
8.  Barnett AJH, Harper R, Toorawa R, et al. Linagliptin monotherapy
    improves glycaemic control in type 2 diabetes patients for who
    metformin therapy is inappropriate. Poster No 823-P, 46th European
    Association for the Study of Diabetes Annual Meeting, 20-14
    September 2010, Stockholm, Sweden.
9.  Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin
    as add-on therapy to a sulphonylurea in inadequately controlled type
    2 diabetes. Poster No 821-P, 46th European Association for the Study
    of Diabetes Annual Meeting, 20-14 September 2010, Stockholm, Sweden.
10. Owens DR, Swallow R, Kugi KA, Woerle HJ. Efficacy and safety of
    linagliptin in persons with type 2 diabetes inadequately controlled
    by a combination of metformin and sulphonylurea: a 24-week
    randomized study. Diabet Med 2011;28(11):1352-1361.
11. Taskinen M-R, et al. Efficacy and safety of linagliptin in Type 2
    diabetes inadequately controlled on metformin monotherapy. Poster No
    579-P from the 70th American Diabetes Association Scientific
    Sessions, 25-29 June 2010, Orlando, Florida, USA.
12. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin
    monotherapy on glycaemic control and markers of β-cell function in
    patients with inadequately controlled type 2 diabetes: a randomized
    controlled trial. Diabetes Obes Metab 2011;13(3):258-267.
13. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and
    safety of initial combination therapy with linagliptin and
    pioglitazone in patients with inadequately controlled type 2
    diabetes: a randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab 2011;13(7):653-661.
14. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy
    provides superior glycaemic control versus placebo or voglibose with
    comparable safety in Japanese patients with type 2 diabetes: a
    randomized, placebo and active comparator-controlled, double-blind
    study. Diabetes Obes Metab 2011;Dec 6 \[Epub ahead of print\].
15. Kawamori R. et al. Linagliptin monotherapy improves glycemic control
    in Japanese patients with T2DM over 12 weeks. Poster number 696-P
    from the 70th American Diabetes Association Scientific Sessions,
    25-29 June 2010, Orlando, Florida, USA
16. Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin has
    similar efficacy to glimepiride but improved cardiovascular safety
    over 2 years in patients with type 2 diabetes inadequately
    controlled on metformin 71th Scientific Sessions of the American
    Diabetes Association, San Diego, California. 2011; Poster 39-LB.
17. Barnett AJH, Harper R, Toorawa R, et al. Linagliptin monotherapy
    improves glycaemic control in type 2 diabetes patients for who
    metformin therapy is inappropriate. Poster No 823-P, 46th European
    Association for the Study of Diabetes Annual Meeting, 20-14
    September 2010, Stockholm, Sweden.
18. Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin
    as add-on therapy to a sulphonylurea in inadequately controlled type
    2 diabetes. Poster No 821-P, 46th European Association for the Study
    of Diabetes Annual Meeting, 20-14 September 2010, Stockholm, Sweden.
19. Owens DR, Swallow R, Kugi KA, Woerle HJ. Efficacy and safety of
    linagliptin in persons with type 2 diabetes inadequately controlled
    by a combination of metformin and sulphonylurea: a 24-week
    randomized study. Diabet Med 2011;28(11):1352-1361.
20. Taskinen M-R, et al. Efficacy and safety of linagliptin in Type 2
    diabetes inadequately controlled on metformin monotherapy. Poster No
    579-P from the 70th American Diabetes Association Scientific
    Sessions, 25-29 June 2010, Orlando, Florida, USA.
21. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin
    monotherapy on glycaemic control and markers of β-cell function in
    patients with inadequately controlled type 2 diabetes: a randomized
    controlled trial. Diabetes Obes Metab 2011;13(3):258-267.
22. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and
    safety of initial combination therapy with linagliptin and
    pioglitazone in patients with inadequately controlled type 2
    diabetes: a randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab 2011;13(7):653-661.
23. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy
    provides superior glycaemic control versus placebo or voglibose with
    comparable safety in Japanese patients with type 2 diabetes: a
    randomized, placebo and active comparator-controlled, double-blind
    study. Diabetes Obes Metab 2011;Dec 6 \[Epub ahead of print\].
24. Kawamori R. et al. Linagliptin monotherapy improves glycemic control
    in Japanese patients with T2DM over 12 weeks. Poster number 696-P
    from the 70th American Diabetes Association Scientific Sessions,
    25-29 June 2010, Orlando, Florida, USA
25. Owens DR, Swallow R, Kugi KA, Woerle HJ. Efficacy and safety of
    linagliptin in persons with type 2 diabetes inadequately controlled
    by a combination of metformin and sulphonylurea: a 24-week
    randomized study. Diabet Med 2011;28(11):1352-1361.
26. Taskinen M-R, et al. Efficacy and safety of linagliptin in Type 2
    diabetes inadequately controlled on metformin monotherapy. Poster No
    579-P from the 70th American Diabetes Association Scientific
    Sessions, 25-29 June 2010, Orlando, Florida, USA.
27. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin
    monotherapy on glycaemic control and markers of β-cell function in
    patients with inadequately controlled type 2 diabetes: a randomized
    controlled trial. Diabetes Obes Metab 2011;13(3):258-267.
28. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and
    safety of initial combination therapy with linagliptin and
    pioglitazone in patients with inadequately controlled type 2
    diabetes: a randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab 2011;13(7):653-661.
29. Kawamori R. et al. Linagliptin monotherapy improves glycemic control
    in Japanese patients with T2DM over 12 weeks. Poster number 696-P
    from the 70th American Diabetes Association Scientific Sessions,
    25-29 June 2010, Orlando, Florida, USA.
30. Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin has
    similar efficacy to glimepiride but improved cardiovascular safety
    over 2 years in patients with type 2 diabetes inadequately
    controlled on metformin 71th Scientific Sessions of the American
    Diabetes Association, San Diego, California. 2011; Poster 39-LB.
31. Owens DR, Swallow R, Kugi KA, Woerle HJ. Efficacy and safety of
    linagliptin in persons with type 2 diabetes inadequately controlled
    by a combination of metformin and sulphonylurea: a 24-week
    randomized study. Diabet Med 2011;28(11):1352-1361.
32. Taskinen M-R, et al. Efficacy and safety of linagliptin in Type 2
    diabetes inadequately controlled on metformin monotherapy. Poster No
    579-P from the 70th American Diabetes Association Scientific
    Sessions, 25-29 June 2010, Orlando, Florida, USA.
33. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin
    monotherapy on glycaemic control and markers of β-cell function in
    patients with inadequately controlled type 2 diabetes: a randomized
    controlled trial. Diabetes Obes Metab 2011;13(3):258-267.
34. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and
    safety of initial combination therapy with linagliptin and
    pioglitazone in patients with inadequately controlled type 2
    diabetes: a randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab 2011;13(7):653-661.
35. Kawamori R. et al. Linagliptin monotherapy improves glycemic control
    in Japanese patients with T2DM over 12 weeks. Poster number 696-P
    from the 70th American Diabetes Association Scientific Sessions,
    25-29 June 2010, Orlando, Florida, USA.
36. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (Gliptins). Clin
    Pharmacokinet 2010;49(9):573-588.
37. Graefe-Mody U, Friedrich C, Port A, et al. Linagliptin, a novel
    DPP-4 inhibitor: no need for dose adjustment in patients with renal
    impairment. Poster No. 822-P, 46th European Association for the
    Study of Diabetes Annual Meeting, 20-24 September 2010, Stockholm,
    Sweden.
38. Pratley R. Inhibition of DPP-4: a new therapeutic approach for the
    treatment of Type 2 diabetes. Curr Med Res Opin 2007;23(4):919-931.